Finance

Oncology company to raise $26M through sale of common stock

Published in Drug Week, May 14th, 2004

Cytogen Corporation (CYTO), a product-driven, oncology-focused biopharmaceutical company, announced that it has entered into purchase agreements for the sale of 2,570,000 shares of its common stock at $10.10 per share through a registered direct offering.

The transaction is expected to provide net proceeds of $24.0 million to Cytogen.

CIBC World Markets Corp. acted as lead placement agent, with JMP Securities, LLC, and ThinkEquity Partners, LLC, acting as coplacement agents for this transaction.

The shares of common stock offered by Cytogen in this transaction were registered under the company's existing shelf registration...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-05-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry